App-Quantinova.ai

Challenges in the diagnosis and investigation of giant cell arteritis during COVID-19 pandemic restrictions: does the Southend pretest probability score help to guide clinical diagnosis?

Jessie Gew - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Giant cell arteritis

N/A

Comprehensive in situ immune phenotyping with the CosMx™ high plex protein assay

Tien Phan-Everson - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors

Federica Pecci - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

EpiScan: A synthetic biology platform for targeted immunopeptidomics

Peter Bruno - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors

Khalil Choucair - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Quantitative spatial profiling of the tumor microenvironment in NSCLC tissue microarray cores using a 6-plex multiplex imaging technology and AI-powered phenotyping analysis

Nicole Couper - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

The effects of negative isolation and aggregate strainers on expanded gamma/delta T cells and their cancer cell cytotoxicity

Georg von Massow - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Zolendronic acid

Identification of novel NSC lung cancer Dark Antigens™ with expression in multiple tumor types, as promising targets for immunotherapies

Rachel Abbott - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell therapy for prostate cancer

Vipul Bhatia - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

IL-12

Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment

Xavier Michelet - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

IL-15

An affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade

Xavier Chauchet - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Immune checkpoint blockade boosts anti-tumour B cell responses in lung adenocarcinoma

Jesse Boumelha - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

N/A

Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition

Dante Bortone - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy.

Silvia Guglietta - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

Danish Memon - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Interferon

Tumor context dictates reliance on TCF1 for response to immunotherapy

Giulia Escobar - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

First in human study of S-488210/S-488211, a cancer peptide vaccine, in patients with advanced solid tumours

Mark Linch - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Peptide vaccine

Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors

Kevin Harrington - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial

H Duygu Saatcioglu - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma

Alexander Greenshields Watson - American Society of Clinical Oncology (ASCO) Society for Immunotherapy of Cancer (SITC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

GP100

Filters

45280 Abstracts